EPL Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/eb68nrkp2b8bhmen2f1u2iwp.pdf

Key Takeaways


Margin Walk: The Currency Squeeze

Kripalu: "I do not think this management team is going to rest till we get back to the levels of the profitability that we enjoyed say for any percentage losses due to transmission, so I just want to be very, very clear about that."

Regional Performance: A Tale of Four Geographies

RegionRevenue GrowthCommentary
America▲ 19.7%Demand scenario remains solid and strong, but significant cost-side pressures persist.
AMESA▲ 16.9%Broad-based growth; pharma has done really well here.
Europe▲ 8.9%Steady growth despite power supply disruptions and currency headwinds from euro and zloty devaluation.
EAP▬ 1.5%Improved from -6% in Q1 but still subdued; zero-tolerance COVID policy continues to hurt day-to-day business, though the overall P&L remains very healthy.

Brazil: The Next Growth Engine

Kripalu: "Ever since we made the announcement and started the investment and our plant is kind of at least the shell of the plant is almost ready now and equipment is on the high, the amount of queries and interest that we have seen from multiple other local and global players is very, very encouraging."

Category & Mix Shift


Sustainability as Competitive Advantage


Guidance & Commitments

CommitmentSpecificsTimeline
Brazil commercial productionCommence commercial productionBy end of FY2023
Platina volumeDouble Platina volume in FY2023; "very much on track"FY2023
Margin restorationRestore EBITDA per tube to levels previously enjoyedNo date given
Input cost trajectoryConsumption cost will come down, partly offset by FXFuture quarters
Freight cost benefitFreight costs coming down to help improve EBITDA marginComing quarters

Key Metrics

MetricQ2 FY23
Revenue growth (constant currency)Double digit
Revenue growth (prevailing currency)9%
AMESA revenue growth16.9%
Americas revenue growth19.7%
Europe revenue growth8.9%
EAP revenue growth1.5%, improved from -6% in Q1 FY23
Personal care & beyond revenue growth17.7%
Oral care revenue growth6.7%
H1 personal care & beyond revenue share47.8%, up 220 bps YoY
EBITDA margin (excl. Brazil setup cost)16.3%, improved 119 bps sequentially
EBITDA margin (incl. Brazil setup cost)16.1%
EBITDA sequential growth22.9%
Net profit (excl. Brazil setup cost)₹48.2 cr, sequential growth of 39.7%
Net profit (incl. Brazil setup cost)₹46.2 cr
Brazil project capex commitment₹138 cr total; ₹130 cr for FY2023